Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Share-based Compensation (2021 - 2025)

Bioventus' Share-based Compensation history spans 5 years, with the latest figure at $3.4 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 70.63% year-over-year to $3.4 million; the TTM value through Dec 2025 reached $12.7 million, down 4.53%, while the annual FY2025 figure was $12.7 million, 4.53% down from the prior year.
  • Share-based Compensation reached $3.4 million in Q4 2025 per BVS's latest filing, up from $3.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $6.1 million in Q4 2021 to a low of -$2.7 million in Q3 2023.
  • Average Share-based Compensation over 5 years is $3.3 million, with a median of $3.3 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: plummeted 159.19% in 2023, then skyrocketed 311.46% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $6.1 million in 2021, then crashed by 43.82% to $3.4 million in 2022, then crashed by 48.28% to $1.8 million in 2023, then grew by 13.58% to $2.0 million in 2024, then soared by 70.63% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Share-based Compensation are $3.4 million (Q4 2025), $3.2 million (Q3 2025), and $3.6 million (Q2 2025).